JPMorgan initiated coverage of Absci (ABSI) with an Overweight rating and no price target Absci is an artificial intelligence-driven platform company developing novel therapeutics, the analyst tells investors in a research note. The firm says the company’s expertise in the computational space has the “attractive potential” in changing how new therapeutics are found. Absci is will reach a major inflection point with the first interim clinical data cut later this year, contends JPMorgan.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABSI:
- Absci announces collaboration with Oracle Cloud Infrastructure, AMD
- Absci Corp. Earnings Call: Strategic Gains Amid Challenges
- Promising Potential of AbSci’s ABS-201 Therapy for Androgenetic Alopecia: A Buy Recommendation
- Promising Developments and Strong Financial Position Bolster AbSci’s Growth Prospects
- AbSci’s Positive Outlook: Strong Financial Position and Promising ABS-101 Developments Support Buy Rating